

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

VOLUNTARY ANNOUNCEMENT
NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR
TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS
ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of an update on the business developments of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that on March 9, 2026, the new drug application (NDA) of Crusekitug injection (anti-IL-17A monoclonal antibody, R&D code: QX002N) independently developed by the Company has been accepted by the National Medical Products Administration (國家藥品監督管理局) (the “**NMPA**”). Details are announced as follows:

Drug name	:	Crusekitug injection
Form	:	Injection
Application	:	Registration and marketing authorisation of domestically manufactured drug
Registration classification	:	Therapeutic biological product, Class 1
Acceptance number	:	CXSS2600039
Proposed Indication	:	Active ankylosing spondylitis (AS) in adults

The application is based on a multicenter, randomised, double-blind, placebo-controlled Phase III clinical study (registration number: CTR20232574). The results of this clinical study were presented as an oral presentation at the annual meeting of the American College of Rheumatology (ACR Convergence) in October 2025. The study results showed that Crusekitug demonstrated significant and sustained improvements in disease activity, signs and symptoms in subjects with active AS who had an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs. It exhibited a favourable safety and tolerability profile during the 52-week treatment and follow-up period. The efficacy of the drug was also significant in the population previously treated with tumor necrosis factor (TNF) inhibitors. Furthermore, Crusekitug effectively reduces edema and inflammation in the spine and sacroiliac joints of subjects, providing clear objective imaging evidence for the drug's ability to suppress disease activity. For more information, please refer to the Company's announcement dated October 28, 2025.

Crusekitug is the first innovative drug developed by the Company with NDA acceptance, and it is also the second biologic product to reach the NDA stage, following SAILEXIN. This signifies that the Company's research and development pipeline is progressively entering a harvest phase.

ABOUT CRUSEKITUG

Crusekitug is a high-affinity monoclonal antibody targeting IL-17A. IL-17A is a member of the IL-17 superfamily of cytokines and a key player in the pathological mechanism of various autoimmune diseases. IL-17A enhances chronic inflammation by inducing the release of and working in synergy with pro-inflammatory cytokines such as interleukin-6 (IL-6) and chemokine CXCL1. Additionally, IL-17A is involved in the regulatory mechanism of bone remodeling and has been identified as a major factor in AS pathogenesis. Crusekitug is designed to specifically bind to IL-17A, including IL-17AA and IL-17AF, thereby blocking their binding to the intended receptor complex, comprised of IL-17RA and IL-17RC, and preventing the subsequent activation of several pro-inflammatory signaling pathways, thereby inhibiting the onset and progression of inflammation.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize QX002N successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, March 9, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.